UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
SCHEDULE 13G
(Rule 13d-102)
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2 )*
Therapeutic Discovery Corp.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
883376204
- --------------------------------------------------------------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement |_|. (A fee
is not required only if the filing person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7).
- ----------
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be filed for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
SCHEDULE 13G
CUSIP No. 883376204
- --------------------------------------------------------------------------------
1 Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Merrill Lynch & Co., Inc.
- --------------------------------------------------------------------------------
2 Check the Appropriate Box If a Member of a Group* a. |_|
b. |_|
- --------------------------------------------------------------------------------
3 SEC Use Only
- --------------------------------------------------------------------------------
4 Citizenship or Place of Organization
Delaware
- --------------------------------------------------------------------------------
5 Sole Voting Power
Number of
Shares None
Beneficially --------------------------------------------------------
Owned By 6 Shared Voting Power
Each
Reporting 463,795
Person --------------------------------------------------------
With 7 Sole Dispositive Power
None
--------------------------------------------------------
8 Shared Dispositive Power
463,795
- --------------------------------------------------------------------------------
9 Aggregate Amount Beneficially Owned by Each Reporting Person
463,795
- --------------------------------------------------------------------------------
10 Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares* |_|
- --------------------------------------------------------------------------------
11 Percent of Class Represented By Amount in Row (9)
5.98%
- --------------------------------------------------------------------------------
12 Type of Reporting Person*
HC, CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
SCHEDULE 13G
CUSIP No. 883376204
- --------------------------------------------------------------------------------
1 Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Merrill Lynch, Pierce, Fenner & Smith Incorporated
- --------------------------------------------------------------------------------
2 Check the Appropriate Box If a Member of a Group* a. |_|
b. |_|
- --------------------------------------------------------------------------------
3 SEC Use Only
- --------------------------------------------------------------------------------
4 Citizenship or Place of Organization
Delaware
- --------------------------------------------------------------------------------
5 Sole Voting Power
Number of
Shares None
Beneficially --------------------------------------------------------
Owned By 6 Shared Voting Power
Each
Reporting 463,630
Person --------------------------------------------------------
With 7 Sole Dispositive Power
None
--------------------------------------------------------
8 Shared Dispositive Power
463,630
- --------------------------------------------------------------------------------
9 Aggregate Amount Beneficially Owned by Each Reporting Person
463,630
- --------------------------------------------------------------------------------
10 Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares* |_|
- --------------------------------------------------------------------------------
11 Percent of Class Represented By Amount in Row (9)
5.98%
- --------------------------------------------------------------------------------
12 Type of Reporting Person*
BD, CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
Item 1 (a) Name of Issuer:
Therapeutic Discovery Corp.
Item 1 (b) Address of Issuer's Principal Executive Offices:
P.O. Box 10051
Palo Alto, CA 94303-0860
Item 2 (a) Names of Persons Filing:
Merrill Lynch & Co., Inc.
Merrill Lynch, Pierce, Fenner & Smith Incorporated
Item 2 (b) Address of Principal Business Office, or, if None, Residence:
Merrill Lynch & Co., Inc.
World Financial Center, North Tower
250 Vesey Street
New York, New York 10281
Merrill Lynch, Pierce, Fenner & Smith Incorporated
World Financial Center, North Tower
250 Vesey Street
New York, New York 10281
<PAGE>
Item 2 (c) Citizenship:
See Item 4 of Cover Pages
Item 2 (d) Title of Class of Securities:
Common Stock
Item 2 (e) CUSIP Number:
883376204
Item 3
Merrill Lynch & Co., Inc. ("ML&Co.") is a parent holding company, in
accordance with ss.240.13d-1(b)(ii)(G). Merrill Lynch, Pierce, Fenner & Smith
Incorporated ("MLPF&S") is a broker-dealer registered under Section 15 of the
Securities Exchange Act of 1934.
Item 4 Ownership
(a) Amount Beneficially Owned:
See Item 9 of Cover Pages. Pursuant to ss. 240.13d-4, ML&Co. and MLPF&S
(the "Reporting Persons") disclaim beneficial ownership of the securities of
Therapeutic Discovery Corp. referred to herein, and the filing of this Schedule
13G shall not be construed as an admission that the Reporting Persons are, for
the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934,
the beneficial owner of any of the securities of Therapeutic Discovery Corp.
referred to herein other than in the case of such held by MLPF&S in proprietary
accounts.
(b) Percent of Class:
See Item 11 of Cover Pages
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
See Item 5 of Cover Pages
(ii) shared power to vote or to direct the vote:
See Item 6 of Cover Pages
(iii) sole power to dispose or to direct the disposition of:
<PAGE>
See Item 7 of Cover Pages
(iv) shared power to dispose or to direct the disposition of:
See Item 8 of Cover Pages
Item 5 Ownership of Five Percent or Less of a Class.
Not Applicable
Item 6 Ownership of More than Five Percent on Behalf of Another
Person.
MLPF&S has discretionary investment authority in respect of certain
customer accounts holding in the aggregate 200 shares of the common stock of
Therapeutic Discovery Corp. on behalf of persons who have the right to receive,
or the power to direct the receipt of dividends from, or the proceeds from the
sale of, such securities. Merrill Lynch Asset Management L.P., d/b/a Merrill
Lynch Asset Management ( "MLAM") , is a wholly-owned subsidiary of ML&Co. and a
Delaware limited partnership with its principal place of business at 800
Scudders Mill Road, Plainsboro, New Jersey. MLAM is an investment adviser
registered under Section 203 of the Investment Advisers Act of 1940. MLAM may be
deemed to be the beneficial owner of less than 1% of the common stock of
Therapeutic Discovery Corp. by virtue of its acting as an investment advisor to
private accounts and investment companies registered under section 8 of the
Investment Company Act of 1940. No such persons has an interest that relates to
more than 5% of the class of securities reported herein.
Item 7 Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company.
See Exhibit A
Item 8 Identification and Classification of Members of the Group.
Not Applicable
<PAGE>
Item 9 Notice of Dissolution of Group.
Not Applicable
Item 10 Certification.
By signing below each of the undersigned certifies that, to the best of
their knowledge and belief, the securities referred to above were acquired in
the ordinary course of business and were not acquired for the purpose of and do
not have the effect of changing or influencing the control of the issuer of such
securities and were not acquired in connection with or as a participant in any
transaction having such purposes or effect.
Signature.
After reasonable inquiry and to the best of my knowledge and belief, each
of the undersigned certifies that the information set forth in this statement is
true.
Merrill Lynch & Co., Inc.
__________________________
Date:
__________________________
Signature:
__________________________
Name: Richard B. Alsop
__________________________
Title: Attorney-in-Fact*
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
__________________________
Date:
__________________________
Signature:
__________________________
Name: Richard B. Alsop
__________________________
Title: Attorney-in-Fact**
- ----------
* Executed pursuant to a Power of Attorney dated November 17, 1995, a copy of
which is attached hereto as Exhibit B.
** Executed pursuant to a Power of Attorney dated November 17, 1995, a copy of
which is attached hereto as Exhibit C.
<PAGE>
Exhibit A to Schedule 13G
ITEM 7 DISCLOSURE RESPECTING SUBSIDIARIES
One of the persons filing this report, Merrill Lynch & Co., Inc., is a
Delaware corporation with its principal place of business at World Financial
Center, North Tower, 250 Vesey Street, New York, New York ("ML&Co."), and a
parent holding company pursuant to ss.240. 13d-1(b)(1)(ii)(G). The relevant
subsidiaries of ML&Co. are Merrill Lynch, Pierce, Fenner & Smith Incorporated
("MLPF&S"), Merrill Lynch Group, Inc. ("ML Group"), Princeton Services, Inc.
("PSI"), Merrill Lynch Asset Management L.P. (d/b/a) Merrill Lynch Asset
Management ("MLAM").
MLPF&S, a Delaware corporation with its principal place of business at
World Financial Center, North Tower, 250 Vesey Street, New York, New York, is a
wholly-owned direct subsidiary of ML&Co. and a broker-dealer registered pursuant
to the Securities Exchange Act of 1934. MLPF&S is the beneficial owner of 5.98%
of the common stock of Therapeutic Discovery Corp.
ML Group, a Delaware coporation with its principal place of business at
World Financial Center, North Tower, 250 Vesey Street, New York, New York, is a
wholly-owned direct subsidiary of ML&Co. and a parent holding company pursuant
to ss.240. 13d-1(b)(1)(ii)(G). ML Group may be deemed to be the beneficial owner
of less than 1% of the common stock of Therapeutic Discovery Corp. by virtue of
its control of its wholly-owned subsidiariy, PSI.
PSI, a Delaware corporation with its principal place of business at 800
Scudders Mill Road, Plainsboro, New Jersey, is a wholly-owned subsidiary of ML
Group and may be deemed to be the beneficial owner of less than 1% of the common
stock of Therapeutic Discovery Corp. by virtue of being the general partner of
MLAM.
MLAM, is a Delaware limited partnership with its principal place of
business at 800 Scudders Mill Road, Plainsboro, New Jersey and is an investment
adviser registered under Section 203 of the Investment Advisers Act of 1940.
MLAM may be deemed to be the beneficial owner of less than 1% of the common
stock of Therapeutic Discovery Corp. by virtue of its acting as investment
advisor to private accounts and investment companies registered under section 8
of the Investment Company Act of 1940.
Pursuant to ss.240.13d-4, ML&Co., MLPF&S, ML Group, PSI, MLAM, disclaim
beneficial ownership of the securities of Therapeutic Discovery Corp. referred
to herein and the filing of this Schedule 13G shall not be construed as an
admission that any such entity is, for the purposes of Section 13(d) or 13(g) of
the Securities Exchange Act of 1934, the beneficial owner of any of the
securities of Therapeutic Discovery Corp. other than in the case of ML&Co. and
MLPF&S, securities of Therapeutic Discovery Corp. held by MLPF&S in proprietary
accounts.
<PAGE>
Exhibit B to Schedule 13G
Power of Attorney
The undersigned, Merrill Lynch & Co., (the "Corporation") a corporation
duly organized under the laws of Delaware, with its principal place of business
at World Financial Center, North Tower, 250 Vesey Street, New York, New York
10281does hereby make, constitute and appoint Richard B. Alsop, Richard D.
Kreuder, Andrea Lowenthal, Gregory T. Russo, or any other individual from time
to time elected or appointed as secretary or an assisitant secretary of the
Corporation, acting severally, each of whose address is Merrill Lynch & Co.,
Inc., World Financial Center, North Tower, 250 Vesey Street, New York, New York
10281, as its true and lawful attorneys-in-fact, for it and in its name, place
and stead (i) to execute on behalf of the Corporation and cause to be filed
and/or delivered, as required under Section 13(d) of the Securities Exchange Act
of 1934 (the "Act") and the regulations thereunder, any number, as appropriate,
of original, copies, or electronic filings of the Securities and Exchange
Commission Schedule 13D or Schedule 13G Beneficial Ownership Reports (together
with any amendments and joint filing agreements under Rule 13d-1(f) (1) of the
Act, as may be required thereto) to be filed and/or delivered with respect to
any equity security (as defined in Rule 13d-1(d) under the Act) beneficially
owned by the undersigned and which must be reported by the undersigned pursuant
to Section 13(d) of the Act and the regulations thereunder, (ii) and generally
to take such other actions and perform such other things necessary to effectuate
the foregoing as fully in all respects as if the undersigned could do if
personally present. This Power of Attorney shall remain in effect until revoked,
in writing, by the undersigned.
IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney,
this 17th day of November, 1995.
MERRILL LYNCH & Co., Inc.
By: /s/ David H. Komansky
----------------------------
Name: David H. Komansky
Title: President and Chief Operating Officer
<PAGE>
Exhibit C to Schedule 13G
Power of Attorney
The undersigned, Merrill Lynch, Pierce, Fenner & Smith Incorporated, ( the
"Corporation") a corporation duly organized under the laws of Delaware, with its
principal place of business at World Financial Center, North Tower, 250 Vesey
Street, New York, New York 10281does hereby make, constitute and appoint Richard
B. Alsop, Richard D. Kreuder, Andrea Lowenthal, Gregory T. Russo, or any other
individual from time to time elected or appointed as secretary or an assisitant
secretary of the Corporation, acting severally, each of whose address is Merrill
Lynch & Co., Inc., World Financial Center, North Tower, 250 Vesey Street, New
York, New York 10281, as its true and lawful attorneys-in-fact, for it and in
its name, place and stead (i) to execute on behalf of the Corporation and cause
to be filed and/or delivered, as required under Section 13(d) of the Securities
Exchange Act of 1934 (the "Act") and the regulations thereunder, any number, as
appropriate, of original, copies, or electronic filings of the Securities and
Exchange Commission Schedule 13D or Schedule 13G Beneficial Ownership Reports
(together with any amendments and joint filing agreements under Rule 13d-1(f)
(1) of the Act, as may be required thereto) to be filed and/or delivered with
respect to any equity security (as defined in Rule 13d-1(d) under the Act)
beneficially owned by the undersigned and which must be reported by the
undersigned pursuant to Section 13(d) of the Act and the regulations thereunder,
(ii) and generally to take such other actions and perform such other things
necessary to effectuate the foregoing as fully in al respects as if the
undersigned could do if personally present. This Power of Attorney shall remain
in effect until revoked, in writing, by the undersigned.
IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney,
this 17th day of November, 1995.
MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
By: /s/ David H. Komansky
--------------------------
Name: David H. Komansky
Title: President and Chief Operating Officer
